Literature DB >> 25842085

Commentary on "aTTom": long-term effects of continuing adjuvant Tamoxifen to 10 years.

Hamdy A Azim1, Ahmed Saadeldeen2.   

Abstract

Year:  2014        PMID： 25842085     DOI： 10.3978/j.issn.2304-3865.2013.12.02

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN： 2304-3865


× No keyword cloud information.
  4 in total

Review 1.  Breast cancer under age 40: a different approach.

Authors:  D Ribnikar; J M Ribeiro; D Pinto; B Sousa; A C Pinto; E Gomes; E C Moser; M J Cardoso; F Cardoso
Journal:  Curr Treat Options Oncol       Date:  2015-04

2.  Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.

Authors:  Li Li; Bingmei Chang; Xiaoyue Jiang; Xueke Fan; Yingrui Li; Teng Li; Shanshan Wu; Jun Zhang; Seyed Kariminia; Qin Li
Journal:  BMC Cancer       Date:  2018-10-12       Impact factor: 4.430

3.  Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer: An observational study in Asian patients.

Authors:  Eun Jung Jung; Ju-Yeon Kim; Jae-Myung Kim; Han Shin Lee; Seung-Jin Kwag; Ji-Ho Park; Taejin Park; Sang-Ho Jeong; Chi-Young Jeong; Young-Tae Ju; Young-Joon Lee; Soon-Chang Hong
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

4.  Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.

Authors:  Eun-Shin Lee; Wonshik Han; Min Kyoon Kim; Jongjin Kim; Tae-Kyung Yoo; Moo Hyun Lee; Kyung Hun Lee; Tae Yong Kim; Hyeong-Gon Moon; Seock-Ah Im; Dong-Young Noh; Eun Sook Lee
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.